Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
2 min synopsisUK scopeSources checked 27 Aug 2026Clinical review pending
!
Escalate
Sudden or rapidly progressive chorea with encephalopathy, fever, severe metabolic disturbance, pregnancy, focal neurology, new dopamine-blocking treatment or marked behavioural risk needs urgent assessment. Stabilise ABCDE, check glucose and medication exposure, and escalate suicidality, inability to swallow, rhabdomyolysis or possible stroke, infection, autoimmune disease or neuroleptic malignant syndrome immediately.
Synopsis
Recognise chorea as a movement phenotype, identify acquired and treatable causes before attributing it to inheritance, and manage suspected Huntington disease through consented genomic testing, multidisciplinary symptom care and family-centred planning.
Chorea consists of brief, irregular, non-rhythmic movements that flow unpredictably between body regions and become incorporated into apparently purposeful activity; it differs from rhythmic tremor and stereotyped tics.
Look for motor impersistence such as an unsustained tongue protrusion or fluctuating milkmaid grip, unpredictable facial movements, fidgeting gait and intrusive distal movements during posture.
Huntington disease is an autosomal dominant neurodegenerative disorder caused by a CAG repeat expansion in HTT; each child of an affected person has a one-in-two chance of inheriting the expansion.
Key red flags
Acquired hemichorea
Abrupt unilateral chorea suggests a contralateral basal ganglia or subthalamic lesion, severe non-ketotic hyperglycaemia or another focal process and needs urgent imaging and metabolic assessment.
Investigation priorities
01
Phenomenology and collateral historyFirst step
Confirm chorea, map progression and identify cognitive, psychiatric, medicine and family clues.
Management branches
New choreaDefine tempo and reversible cause
Irregular involuntary movements are newly observed or rapidly worsening.
1. Confirm choreic phenomenology, establish sudden versus progressive onset, examine focal neurology and assess cognition, behaviour, temperature and swallowing safety.
2. Reconcile prescription, antiemetic, psychiatric, dopaminergic and recreational exposures with the movement timeline, including recently stopped agents.
Key medicines
TetrabenazineA movement-disorder specialist starts a low daily dose and titrates in small divided increments to the lowest effective regimen, following the current BNF and product maximum rather than a fixed target.
Specialist-selected antipsychoticUse the lowest effective oral dose with slow titration when psychosis, severe irritability or chorea provides a documented indication; medicine and schedule depend on metabolic and motor risk.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
NHS Huntington disease overviewCurrent UK patient-facing information on presentation, testing, inheritance and multidisciplinary support.